SCHEMBL1473250

SCHEMBL1473250

NC1CCc2ccccc2N1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.44
HTR2C P28335 3/20 0.41
HTR2B P41595 3/20 0.41
SRD5A1 P18405 2/20 0.39
ANPEP P15144 4/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CDK4 P11802 1/20 0.38
ALOX15 P16050 1/20 0.38
CCND1 P24385 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2A P28223 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6652555 0.79 AADAT (0.46) PLAUHTR2CHTR2BMEN1KMT2A
SCHEMBL23346885 0.78 PLAU (0.42) PLAUHTR2CHTR2BSRD5A1ANPEP
SCHEMBL9685608 0.78 TSHR (0.41) PLAUHTR2CHTR2BSRD5A1ANPEP
SCHEMBL9396982 0.78 GAA (0.50) HTR2CHTR2BSRD5A1TSHRMEN1
SCHEMBL8554748 0.76 TSHR (0.42) PLAUHTR2CHTR2BSRD5A1TSHR
SCHEMBL8554573 0.72 MTNR1A (0.41) TSHRGAASMN1; SMN2CHRM2CHRM1
SCHEMBL28510390 0.71 ANPEP (0.50) SRD5A1ANPEP
SCHEMBL7387071 0.70 ALDH1A1 (0.45) TSHRALDH1A1GAA
SCHEMBL21965899 0.70 MTNR1A (0.49) MEN1ALDH1A1KMT2AHTR2ACHRM2
SCHEMBL7387073 0.70 ALDH1A1 (0.53) TSHRMEN1ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1413286-B1 Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent OREAL (FR) 2009-04-22 EP claimed
WO-2007071688-A1 COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, A PARTICULAR OXIDATION BASE AND A COUPLER L'ORÉAL (FR) 2007-06-28 WO claimed
EP-2175830-B1 COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES ORÉAL L (FR) 2015-09-30 EP disclosed
US-8557838-B2 Immune response modifier formulations containing oleic acid and methods MEDICIS PHARMACEUTICAL CORPORATION (US) 2013-10-15 US disclosed
CN-101939313-B 3,8-diaminotetrahydroquinoline derivative ZERIA PHARM CO LTD 2013-05-22 CN disclosed
US-20120237551-A1 IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-09-20 US disclosed
US-8043385-B2 Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof L'OREAL S.A. (FR) 2011-10-25 US disclosed
US-8002847-B2 Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes L 'OREAL S.A. (FR) 2011-08-23 US disclosed
US-7939555-B2 Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-05-10 US disclosed
US-7928116-B2 Method of treating actinic keratosis 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-04-19 US disclosed
US-7928118-B2 Reduction of imiquimod impurities in pharmaceutical creams 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-04-19 US disclosed
US-20100120831-A1 METHODS FOR IMPROVING IMIQUIMOD AVAILABILITY AT TWO MONTHS, FOUR MONTHS AND SIX MONTHS BETWEEN REFINED AND COMPENDIAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-05-13 US disclosed
US-20100120832-A1 METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST FOUR MONTHS STORAGE) 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-05-13 US disclosed
US-20100120829-A1 X-FOLD LESS IMIQUIMOD IMPURITIES AT SIX MONTHS BETWEEN REFINED AND COMPENDIAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-05-13 US disclosed
EP-2175830-A2 COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES L'Oreal (FR) 2010-04-21 EP disclosed
US-7655672-B2 Immune response modifier formulations containing oleic acid and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-02-02 US disclosed
US-20090093514-A1 IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS 3M INNOVATIVE PROPERTIES COMPANY 2009-04-09 US disclosed
WO-2009016061-A2 COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES L'OREAL (FR) 2009-02-05 WO disclosed
WO-2007071688-A1 COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, A PARTICULAR OXIDATION BASE AND A COUPLER L'ORÉAL (FR) 2007-06-28 WO disclosed
US-20070123558-A1 IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS BAUSCH & LOMB INCORPORATED 2007-05-31 US disclosed